NextCure, Inc. financial data

Symbol
NXTC on Nasdaq
Industry
Pharmaceutical Preparations
Location
9000 Virginia Manor Road, Suite 200, Beltsville, MD
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.07K % -44.3%
Debt-to-equity 16.5 % +64.6%
Return On Equity -62.5 % -39.8%
Return On Assets -53.7 % -32.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28M shares +0.37%
Common Stock, Shares, Outstanding 28M shares +0.49%
Entity Public Float 49.2M USD -57.4%
Common Stock, Value, Issued 28K USD 0%
Weighted Average Number of Shares Outstanding, Basic 28M shares +0.49%
Weighted Average Number of Shares Outstanding, Diluted 28M shares +0.49%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 44.4M USD -9.22%
General and Administrative Expense 16.1M USD -22.1%
Operating Income (Loss) -63.1M USD +9.39%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -58.5M USD +10.7%
Earnings Per Share, Basic -2.09 USD/shares +11.1%
Earnings Per Share, Diluted -2.09 USD/shares +11.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.7M USD +41.9%
Assets, Current 78.7M USD -35.9%
Property, Plant and Equipment, Net 6.17M USD -37.4%
Operating Lease, Right-of-Use Asset 3.42M USD -25.1%
Other Assets, Noncurrent 2.07M USD -27.5%
Assets 90.3M USD -35.4%
Accounts Payable, Current 3.61M USD +38.9%
Employee-related Liabilities, Current 992K USD -39.5%
Accrued Liabilities, Current 3.94M USD -6.83%
Liabilities, Current 8.67M USD +32.4%
Operating Lease, Liability, Noncurrent 5.39M USD -12%
Other Liabilities, Noncurrent 693K USD -15%
Liabilities 14.8M USD +9.39%
Accumulated Other Comprehensive Income (Loss), Net of Tax 76K USD
Retained Earnings (Accumulated Deficit) -369M USD -18.9%
Stockholders' Equity Attributable to Parent 75.6M USD -40.2%
Liabilities and Equity 90.3M USD -35.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.6M USD +14.7%
Net Cash Provided by (Used in) Financing Activities 1K USD
Net Cash Provided by (Used in) Investing Activities 17.9M USD -1.33%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 28M shares +0.49%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.28M USD +57.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.7M USD +41.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 19K USD -9.52%
Deferred Tax Assets, Valuation Allowance 99M USD +24.1%
Deferred Tax Assets, Gross 100M USD +23.5%
Operating Lease, Liability 6.12M USD -9.41%
Payments to Acquire Property, Plant, and Equipment 37K USD -85.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -57.8M USD +9.29%
Lessee, Operating Lease, Liability, to be Paid 7.54M USD -12.9%
Property, Plant and Equipment, Gross 29.3M USD +2.58%
Operating Lease, Liability, Current 656K USD +26.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.36M USD +11.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.21M USD +7.72%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.42M USD -25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.4M USD +3.03%
Deferred Tax Assets, Operating Loss Carryforwards 56.4M USD +13.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.44M USD +3.01%
Operating Lease, Payments 1.03M USD +12.6%
Additional Paid in Capital 444M USD +1.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.38M USD -10.3%
Share-based Payment Arrangement, Expense 6.8M USD -20.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%